Core Viewpoint - Heng Rui Medicine (600276.SH) has received approval from the National Medical Products Administration for clinical trials of SHR-9539 injection and HRS-3738 tablets, marking a significant step in its drug development pipeline [1] Group 1: SHR-9539 Injection - SHR-9539 injection is a Class 1 therapeutic biological product that targets and kills multiple myeloma cells by activating T cells [1] - Currently, there are no similar drugs approved for market in China [1] - The cumulative R&D investment for the SHR-9539 injection project is approximately 39.93 million yuan [1] Group 2: HRS-3738 Tablets - HRS-3738 tablets are a next-generation CRBN E3 ubiquitin ligase modulator that affects the proliferation of hematological tumor cells by degrading specific substrates [1] - The drug has potential advantages in substrate degradation capability and overcoming drug resistance [1] - There are no similar drugs approved for market domestically or internationally [1] - The cumulative R&D investment for the HRS-3738 tablet project is approximately 63.63 million yuan [1]

Group 1 - Sichuan Chengyu's wholly-owned subsidiary plans to acquire 85% equity of Hubei Jingyi Company for 2.409 billion yuan, enhancing the company's control over highway projects [1] - Huadian Technology signed contracts worth approximately 815 million yuan with Huadian Technology Group for a wind power hydrogen production project [2] - Dongfang Cable and its subsidiary won projects totaling approximately 3.125 billion yuan, accounting for 34.37% of the company's audited revenue for 2024 [3] Group 2 - Heng Rui Medicine received approval for clinical trials of SHR-2906 injection, a self-developed biopharmaceutical aimed at weight control and metabolic regulation [4] - Qingdao Port plans to invest approximately 15.7 billion yuan in two terminal projects [5] - Jingu Co. received a notification to supply low-carbon wheels for two export models to a major domestic car manufacturer, with production expected in 2026 [6] Group 3 - ST Xingguang won a procurement project worth approximately 22.955 million yuan, accounting for 11.96% of the company's revenue for 2024 [7] - Xinbo Co. plans to jointly invest in an alloy materials research institute with partners, focusing on high-performance materials for various industries [8] - Tianqi Lithium's third-phase lithium concentrate expansion project has been completed and is undergoing trial production, with a total capacity of 2.14 million tons per year [9] Group 4 - Changfei Fiber reported that new fiber optic products related to data centers represent a small proportion of total demand [10] - Dongfang Bio's subsidiaries obtained multiple medical device registration certificates, including various testing kits [11] - Xiugang Co. plans to use up to 500 million yuan of idle fundraising for cash management in safe, liquid investment products [12] Group 5 - Jifeng Co. received a project designation for passenger car seat assemblies from a European luxury brand, with a total lifecycle value of approximately 9.8 billion yuan [13] - CanSino initiated Phase I clinical trials for a combined vaccine, completing the first subject enrollment [14] - Dayu Water-saving's subsidiary pre-won a drainage project worth 140 million yuan and another project worth 1 billion yuan [15] Group 6 - Yutong Pharmaceutical's subsidiary received clinical trial approval for YKYY032 injection for treating hyperlipoproteinemia [17] - Diweier announced the departure of a core technical personnel, impacting its technical leadership [18] - Weilang Co.'s controlling shareholder received regulatory measures from the Shandong Securities Regulatory Bureau for failing to fulfill a commitment [19] Group 7 - Xiehe Electronics invested 5 million yuan in a private equity fund focusing on hard technology sectors [20] - Phoenix Optical received a government subsidy of 4.7053 million yuan, representing 35% of its projected net profit for 2024 [21] - China State Construction reported a 0.9% year-on-year increase in new contracts signed in the first 11 months of 2025, totaling 4.0408 trillion yuan [22] Group 8 - Nanguang Energy's pumped storage power station units 1 and 2 have entered trial operation, with units 3 and 4 expected to follow by year-end [23] - Jindalai plans to invest 280 million yuan to acquire a 34% stake in Yunnan Jici Medical Technology [24] - Geer Software terminated its planned acquisition of a majority stake in Weipin Zhiyuan due to failure to reach agreement on key terms [25] Group 9 - Ningbo Fubang completed the absorption merger of its wholly-owned subsidiary, inheriting all assets and liabilities [26] - Zhongyuan Neipei signed a strategic cooperation framework agreement with Ningbo Puzhi Company for humanoid robot-related business [28] - Gongyuan Co. announced a business integration and relocation of its production lines in the East China region [29] Group 10 - Chlor-alkali Chemical's subsidiary plans to invest 2.975 billion yuan in a comprehensive utilization project for waste salt [30] - Kain Technology announced the departure of a core technical personnel, impacting its research capabilities [31] - ST Renfu received approval for clinical trials of a new drug for idiopathic pulmonary fibrosis [32] Group 11 - Sanbo Brain Science's established brain science fund has completed registration with the Asset Management Association of China [33] - Tongyou Technology plans to apply for a 70 million yuan credit line from Beijing Bank, using its property as collateral [34] - Bai Ao Intelligent signed a significant equipment sales contract worth approximately 27.5021 million yuan [35] Group 12 - ST Xinyan received all restructuring investment funds totaling 2.239 billion yuan, entering the execution phase of its restructuring plan [36] - Dalu Real Estate's subsidiary decided to terminate a planned acquisition of a 60% stake in Beijing Chengzhu Real Estate [38] - Huiyu Pharmaceutical's products received marketing approval in Italy and Norway [39]

Core Viewpoint - Heng Rui Medicine (600276.SH) has received approval from the National Medical Products Administration for clinical trials of injectable acetic acid leuprolide microspheres, which will be conducted shortly [1] Group 1: Product Information - Acetic acid leuprolide is a GnRH analog used for the treatment of prostate cancer [1] - The original product LEUPLIN® Pro was developed by Takeda Pharmaceutical Company and was approved for market in Japan in November 2015, but has not yet been launched in China [1] - The formulation and dosage of the injectable acetic acid leuprolide microspheres differ from the already marketed injectable leuprolide microspheres in China, classifying it as a generic version of an overseas product that is not yet available domestically [1] Group 2: R&D Investment - The cumulative research and development investment for the injectable acetic acid leuprolide microspheres project has reached approximately 24.68 million yuan [1]

Core Viewpoint - Heng Rui Medicine (600276.SH) announced that its subsidiary, Beijing Shengdi Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial of SHR-2906 injection, which is expected to begin shortly [1] Group 1: Product Development - SHR-2906 injection is a self-developed therapeutic biological product aimed at regulating glucose and lipid metabolism, controlling weight, and improving the metabolic environment in the body [1] - The drug is anticipated to have a synergistic effect in reducing energy intake and promoting energy expenditure, potentially offering clinical efficacy in treating overweight and obesity [1] - Currently, there are no similar drugs approved for market release domestically or internationally [1] Group 2: Financial Investment - The cumulative research and development investment for the SHR-2906 injection project has reached approximately 17.06 million yuan [1]

Core Viewpoint - Heng Rui Medicine (600276.SH) has received approval from the National Medical Products Administration for clinical trials of SHR-2906 injection, a self-developed therapeutic biological product aimed at weight control and metabolic regulation [1] Group 1: Product Development - SHR-2906 injection is designed to reduce energy intake and promote energy expenditure, potentially improving metabolic conditions and offering clinical efficacy in treating overweight and obesity [1] - Currently, there are no similar drugs approved for market release domestically or internationally [1] Group 2: Financial Investment - The total research and development investment for the SHR-2906 injection project has reached approximately 17.06 million yuan [1]

Core Insights - China is transitioning from a generic drug manufacturer to a pharmaceutical innovation hub, with infrastructure and R&D capabilities comparable to global leaders [1][3] - The China Pharmaceutical Innovation and Invention Index (CPIII) was launched to highlight this shift, marking the first standalone ranking after 14 years of a global index [2] Group 1: Innovation and Efficiency - Chinese companies are becoming more efficient in drug development, with the average cost to bring a new medicine to market being approximately US$1 billion for companies like Hengrui, compared to the global average of around US$5 billion [3] - Early-stage biotech companies in China are engaging in extensive clinical trial programs, a practice that is less common in Europe or the US [3] Group 2: Market Position and Rankings - China is increasingly seen as a destination for global players seeking novel assets, especially in oncology, where a significant number of branded products will face patent expirations by 2030 [4] - Jiangsu Hengrui Pharmaceuticals ranked first in the CPIII, followed by BeOne, based on various measures among 30 evaluated mainland companies [4][5] Group 3: Index Structure - The CPIII consists of two sub-indices: the innovation index, which assesses how effectively companies convert inventions into clinical and commercial value, and the invention index, which tracks the creation of novel drugs and technologies [5] - Hengrui is noted for its solid tumor treatments, while BeOne is recognized for its BTK inhibitor zanubrutinib and PD-1 inhibitor tislelizumab for cancer therapies [5]

证券代码：600276 证券简称：恒瑞医药 公告编号：临 2025-203 江苏恒瑞医药股份有限公司 关于获得药物临床试验批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，江苏恒瑞医药股份有限公司（以下简称"公司"）及子公司上海恒瑞 医药有限公司、山东盛迪医药有限公司、成都盛迪医药有限公司收到国家药品监 督管理局（以下简称"国家药监局"）核准签发关于 HRS-6208 胶囊、HRS-6209 胶囊、HRS-8080 片、HRS-1358 片、HRS-5041 片的《药物临床试验批准通知书》， 将于近期开展临床试验。现将相关情况公告如下： 二、药品的其他情况 HRS-6208 是一种新型、高效、选择性的小分子抑制剂，能够强效且高选择 性地抑制靶点的磷酸化激活，影响细胞周期和转录活性，进而抑制肿瘤细胞增殖， 发挥抗肿瘤作用。经查询，目前国内外尚无同类产品获批上市。截至目前， HRS-6208 相关项目累计研发投入约 3,814 万元。 三、风险提示 药品 名称 HRS-6208 胶囊 HRS-6209 胶囊 ...

证券代码：600276 证券简称：恒瑞医药 公告编号：临 2025-205 申请事项：临床试验 受 理 号：CXSL2500799 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，2025 年 9 月 17 日受理的 SHR-2906 注射液临床试验申请符合药品注册的有关要求，同 意本品开展超重或肥胖的临床试验。 二、药物的其他情况 SHR-2906 注射液是公司自主研发的一种治疗用生物制品，预期可在减少能 量摄入、促进能量消耗等调节糖脂代谢、控制体重方面具有协同作用，同时改善 体内代谢环境，有望发挥治疗超重和肥胖的临床疗效。目前国内外尚无同类药物 获批上市。截至目前，SHR-2906 注射液相关项目累计研发投入约为 1,706 万元。 江苏恒瑞医药股份有限公司 关于获得药物临床试验批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，江苏恒瑞医药股份有限公司（以下简称"公司"）子公司北京盛迪医 药有限公司收到国家药品监督管理局（以下简称"国家药监局"）核准签发关于 SHR-2906 注射液的《 ...

江苏恒瑞医药股份有限公司 关于获得药物临床试验批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，江苏恒瑞医药股份有限公司（以下简称"公司"）及子公司苏州盛迪 亚生物医药有限公司、上海恒瑞医药有限公司收到国家药品监督管理局（以下简 称"国家药监局"）核准签发关于 SHR-9539 注射液、HRS-3738 片的《药物临床 试验批准通知书》，将于近期开展临床试验。现将相关情况公告如下： 证券代码：600276 证券简称：恒瑞医药 公告编号：临 2025-204 SHR-9539 注射液为 1 类治疗用生物制品，通过募集和活化 T 细胞，可以发 挥靶向杀伤多发性骨髓瘤细胞的作用。目前国内尚未有同类药物获批上市。截至 目前，SHR-9539 注射液相关项目累计研发投入约为 3,993 万元。 HRS-3738 片为新一代高效 CRBN E3 泛素连接酶调节剂，通过降解特异性底 物影响血液瘤细胞的增殖，具有降解底物能力强和克服耐药的潜在优势。经查询， 国内外未有同类药物获批上市。截至目前，HRS-3738 片相关项 ...

证券代码：600276 证券简称：恒瑞医药 公告编号：临 2025-202 江苏恒瑞医药股份有限公司 关于获得药物临床试验批准通知书的公告 受 理 号：CYHL2500159 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，2025 年 8 月 29 日受理的注射用醋酸亮丙瑞林微球临床试验申请符合药品注册的有关 要求，同意本品开展前列腺癌的临床试验。 二、药物的其他情况 醋酸亮丙瑞林是 GnRH 类似物，用于治疗前列腺癌。原研产品 LEUPLIN®Pro 由武田药品工业株式会社开发，2015 年 11 月获日本 PMDA 批准上市，尚未在国 内上市。本品用法用量与中国已上市的注射用亮丙瑞林微球不同，属仿制境外已 上市但境内未上市的原研药品。截至目前，注射用醋酸亮丙瑞林微球相关项目累 计研发投入约 2,468 万元。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，江苏恒瑞医药股份有限公司（以下简称"公司"）子公司上海恒瑞医 药有限公司收到国家药品监督管理局（以下简称"国家药监局"）核准签发关于 注射用醋酸亮 ...